参考文献/References:
[1] Molitch ME.Nonfunctioning pituitary tumors[J].Handb Clin Neurol,2014,124:167-184.DOI:10.1016/B978-0-444-59602-4.00012-5.
[2] Raverot G,Jouanneau E,Trouillas J.Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies[J].Eur J Endocrinol,2014,170(4):R121-R132. DOI:10.1530/EJE-13-1031.
[3] Bronte V,Brandau S,Chen SH,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J].Nat Commun,2016,7:12150.DOI:10.1038/ncomms12150.
[4] Gotwals P,Cameron S,Cipolletta D,et al.Prospects for combining targeted and conventional cancer therapy with immunotherapy[J].Nat Rev Cancer,2017,17(5):286-301.DOI:10.1038/nrc.2017.17.
[5] Zaretsky JM,Garcia-Diaz A,Shin DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma[J].N Engl J Med,2016,375(9):819-829.DOI:10.1056/NEJMoa1604958.
[6] Komohara Y,Jinushi M,Takeya M.Clinical significance of macrophage heterogeneity in human malignant tumors[J].Cancer Sci,2014,105(1):1-8.DOI:10.1111/cas.12314.
[7] Lu JQ,Adam B,Jack AS,et al.Immune cell Infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas[J].Endocr Pathol,2015,26(3):263-272.DOI:10.1007/s12022-015-9383-6.
[8] Allard B,Aspeslagh S,Garaud S,et al.Immuno-oncology-101: overview of major concepts and translational perspectives[J].Semin Cancer Biol,2018,52(Pt 2):1-11.DOI:10.1016/j.semcancer.2018.02.005.
[9] Ma L,Li G,Su Y,et al.The soluble major histocompatibility complex class Ⅰ-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma[J].J Clin Neurosci,2010,17(2):241-247.DOI:10.1016/j.jocn.2009.05.023.
[10] 刘晓璇,张静,刘兰霞.免疫检查点抑制剂在肿瘤治疗中的应用进展[J].国际生物医学工程杂志,2017,40(4):275-279.DOI:10.3760/cma.j.issn.1673-4181.2017.04.010.
[11] Richardson TE,Shen ZJ,Kanchwala M,et al.Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis[J].J Neuropathol Exp Neurol,2017,76(10):874-882.DOI:10.1093/jnen/nlx072.
[12] Heshmati HM,Kujas M,Casanova S,et al.Prevalence of lymphocytic infiltrate in 1400 pituitary adenomas[J].Endocr J,1998,45(3):357-361.
[13] Lupi I,Manetti L,Caturegli P,et al.Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma[J].J Clin Endocrinol Metab,2010,95(1):289-296. DOI:10.1210/jc.2009-1583.
[14] Tumeh PC,Harview CL,Yearley JH,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-571.DOI:10.1038/nature13954.
[15] Wang P,Wang T,Yang Y,et al.Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: a case report and review of the literatures[J].Medicine(Baltimore),2017,96(49):e9056.DOI:10.1097/MD.0000000000009056.
[16] Mei Y,Bi WL,Greenwald NF,et al.Increased expression of programmed death ligand 1(PD-L1)in human pituitary tumors[J].Oncotarget,2016,7(47):76565-76576.DOI:10.18632/oncotarget.12088.
[17] De Rosa V,Di Rella F,Di Giacomo A,et al.Regulatory T cells as suppressors of anti-tumor immunity: role of metabolism[J].Cytokine Growth Factor Rev,2017,35:15-25.DOI:10.1016/j.cytogfr.2017.04.001.
[18] Ryder M, Callahan M, Postow MA,et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution[J].Endocr Relat Cancer,2014,21(2):371-381. DOI:10.1530/ERC-13-0499.
[19] Lam T,Chan MM,Sweeting AN,et al.Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series[J].Intern Med J,2015,45(10):1066-1073.DOI:10.1111/imj.12819.
[20] Iwama S,De Remigis A,Callahan MK,et al.Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J].Sci Transl Med,2014,6(230):230ra45.DOI:10.1126/scitranslmed.3008002.
[21] Wu JL,Qiao JY,Duan QH.Significance of TNF-α and IL-6 expression in invasive pituitary adenomas[J].Genet Mol Res,2016,15(1).DOI:10.4238/gmr.15017502.
[22] Tichomirowa M,Theodoropoulou M,Lohrer P,et al.Bacterial endotoxin(lipopolysaccharide)stimulates interleukin-6 production and inhibits growth of pituitary tumour cells expressing the toll-like receptor 4[J].J Neuroendocrinol,2005,17(3):152-160.DOI:10.1111/j.1365-2826.2005.01286.x.
[23] Tsukamoto H,Fujieda K,Senju S,et al.Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity[J].Cancer Sci,2018,109(3):523-530.DOI:10.1111/cas.13433.
[24] Chen L,Liu Y,Hou Y,et al.Expression and structure of interleukin 4 receptor(IL-4R)complex in human invasive pituitary adenomas[J].Neurosci Lett,2007,417(1):30-35. DOI:10.1016/j.neulet.2007.02.070.